Scendea

Don't miss the opportunity to meet with the Scendea #BIO2026 team next month! Book a meeting directly: partner.bio.org/conference/86/… - #RegulatoryAffairs #ComplianceSupport #GlobalAgencies #MeetOurExperts #NetworkingOpportunity

Are you developing gene therapies or gene editing products in the UK? Discover how our team can support you in assessing the impact of this MHRA consultation and preparing responses. Book a meeting to learn more: scendea.com/contact - #GeneTherapy

We are excited to announce that our Regional Business Development Manager, Asia-Pacific, Daniel Berg, will be attending ARCS Australia this June! Get in touch to book a meeting: scendea.com/contact - #ARCS2026 #ClinicalResearch

How confident are you in your GxP compliance readiness? Meet Scendea’s compliance experts to explore how our GxP Audit Services can strengthen your quality systems, enhance inspection readiness, and support ongoing compliance: scendea.com/contact

The FDA has opened a public docket to solicit input and comments on its efforts with respect to drug repurposing to address unmet medical needs. Get in touch to learn more: scendea.com/contact

The EMA has updated a series of assessment timetable documents relating to initial marketing authorisation applications. Get in touch to discuss how the updated EMA timetables may affect your strategy: scendea.com/contact

Today, on Clinical Trials Day, Scendea would like to honour the dedication of healthcare professionals, researchers, and participants who have revolutionised healthcare by bringing innovative treatments to light through clinical trials. - #CTD2026 #clinicaltrialsday2026

We are proud to share that Scendea is now a certified B Corporation™! Watch our journey below and learn more about what being a B Corp means to Scendea. - #BCorp #BCorpCertified #BusinessAsAForceForGood #ESG #Sustainability #LifeAtScendea

Read and download the whitepaper to discover how well-designed control strategies help safeguard quality, safety, and efficacy across biopharmaceutical development and manufacturing: scendea.com/articles/imple…

Our upcoming visits to Philadelphia are fast approaching! Scendea's Director, Paul Cronin, will be in the city from June 2 - 4 and June 15 - 17, attending CPHI Americas and DIA 2026. To arrange a meeting, please get in touch: scendea.com/contact

Are you attending the 2026 ASCO Annual Meeting in Chicago? Would you be open to meeting with Paul and Dmitry at ASCO? Get in touch to book a meeting: scendea.com/contact - #ASCO2026 #ChicagoEvents #MedicalConsultation #RegulatoryAffairs #MedicinalProductDevelopment

A reminder that our Director, Paul Cronin, will be attending CPHI Americas. Get in touch to schedule a meeting with Paul: scendea.com/conact - #CPHI #PharmaceuticalIndustry #NetworkingEvent #BusinessOpportunities

Our new whitepaper, authored by Scendea's Head of CMC and Principal Consultant, Dr James Parsley, explores how effective control strategies can be applied across diverse biopharmaceutical platforms. Read and download the whitepaper, today: scendea.com/articles/imple…

The FDA has issued a final guidance describing how it applies flexibility to the CMC requirements for human CGT products being developed for BLAs. Scendea.com/contact - #FDAGuidance #CellularTherapy #GeneTherapy #ATMPs

Outsourcing to CROs and CDMOs does not remove regulatory responsibility. Book a call with our compliance experts to discover how we can support: scendea.com/contact - #CRO #CDMO #RegulatoryCompliance #QualityControl #PatientSafety #Oversight #RiskManagement #InspectionReady

The FDA has announced that it is piloting one-day inspectional assessments as part of a broader initiative to make its inspectional resources more targeted and efficient. Book a meeting, today: scendea.com/contact - #FDAInspections #InspectionReadiness

Are you attending #BIO2026? For support with your product development, regulatory strategy, and compliance activities, book a meeting with our BIO team, today: partner.bio.org/conference/86/… - #BIOInternationalConvention #ProductDevelopment

A reminder that Paul Cronin and Dr Dmitry Zamoryakhin will be attending the 2026 ASCO Annual Meeting, taking place May 29 - June 2, 2026. Please get in touch to arrange meeting: scendea.com/contact - #ASCO2026 #Oncology #ClinicalDevelopment #Biotech #Pharma #Scendea

We are delighted to announce that Dr Paul Williamson has joined the Scendea team at Principal Medical Consultant! - Discover our full team of global experts: scendea.com/about - #LifeAtScendea #PharmaceuticalDevelopment #ClinicalExpertise

The #MHRA has released several important updates across clinical trials, including new and updated guidance on GCP inspections, safety reporting, trial modifications, quality and risk proportionality, trial close-out procedures, and ILAP.